tirzepatide pulled from market Aspen wins approval to Lilly's Mounjaro for weight loss in South Africa Patent attorney: Novo Nordisk must

The SURMOUNT-4 trial showed that stopping treatment led to weight regain, while continued use maintained and even increased weight loss (25.3% total at 88 weeks)

The team started with traditional statistical analysis approaches, but it wasnt until they employed an unsupervised machine learning model that the connections between location, income, race, ethnicity and social vulnerability were discovered

This is the most legitimate pathway right now

Improved adherence Side effects have been called out as a main reason that people stop taking a GLP-1

A lot of physicians will prescribe the injections as an essential part of long-term weight management

Weight Loss Tirzepatide: -21.5% vs Semaglutide: -14.5% Substantial divergence with implications for long-term outcomes